← Research library

Cyclontane and sodium oxybate pharmaceutical composition for desynchronosis

Patent disclosure · 2018

What the patent describes
Desynchronized rats and mouse safety observations for Cyclontane plus sodium oxybate; no human jet-lag trial.
Reported evidence
The combination was investigated for activity rhythms, performance, operant learning and EEG sleep. REM duration exceeded the untreated desynchronosis group, but REM latency remained prolonged relative to baseline: recovery was incomplete.

Wheel activity · Approximately 700 revolutions with the combination versus 200 with saline; baseline about 900 · Desynchronized rats · Third day

Reported patent results

Reported findings

Some activity and REM-sleep measures improved relative to untreated desynchronization, while sleep timing remained abnormal.

Desynchronized rats and mouse safety observations for Cyclontane plus sodium oxybate; no human jet-lag trial.

Population or model Desynchronized rats and mouse safety observations for Cyclontane plus sodium oxybate; no human jet-lag trial.

Results · Description: wheel-running results, sleep-wake narratives around Tables 2–3 and 14-day observation.
MeasureResultComparison, timing and statistics
Wheel activityApproximately 700 revolutions with the combination versus 200 with saline; baseline about 900Desynchronized rats · Third day
REM-sleep durationReported 1.7-fold longer than untreated desynchronization; 62.5% versus 30% exceeded the stated REM thresholdThreshold: REM duration >50% of the baseline group average
Persisting abnormalityREM-onset latency remained approximately twice baseline; wakefulness remained elevatedImprovement versus injury did not mean normalization
Acute observationsNo deaths or listed overt neurological/behavioral abnormalities reportedAnimal observations only · 14 days

The combination does not isolate Cyclontane, and sleep comparisons vary by experiment. Animal safety observations do not establish human safety of this combination.

Source for these results ↗ · Reviewed 2026-11-06

Patent claims and provenance

Use. Later Cyclontane use claims and experimental support; neither a grant nor a comparator establishes human efficacy.

A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.

Publication
RU2674342C2 ↗ · 2018-12-07
Earliest priority / filing
2016-11-28 / 2016-11-28
Original applicant / assignee
Российская Федерация, от имени которой выступает Министерство обороны Российской Федерации
Indexed status
Not shown; official status unverified · checked 2026-11-06
Patent family
62557472 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Pharmaceutical composition of 1-hydroxy-4-cyclohexylaminoadamantane hydrochloride and sodium salt of 4-hydroxymic acid, improving mental and physical efficiency when having desynchronosis

Inventors: Сергей Борисович Середенин; Борис Михайлович Пятин; Нина Ивановна Авдюнина; Любовь Николаевна Грушевская; Надежда Михайловна Зайцева; Константин Викторович Алексеев; Евгения Викторовна Блынская; Анна Сергеевна Михеева; Людмила Михайловна Гаевая; Мария Сергеевна Сергеева; Татьяна Александровна Воронина; Светлана Александровна Литвинова; Инга Геннадиевна Капица; Елена Анатольевна Иванова; Татьяна Сергеевна Калинина.

RU2674342C2

Original patent PDF ↗

Patent collection and status interpretation →

Study limitations and source details

Study limitations

  • Combination findings cannot establish Cyclontane’s independent effect; patent evidence does not establish human efficacy or safety.
  • No clinical sleep benefit or safe self-use regimen follows from these experiments.

Source details

Patent

Selected source passages checked; complete methods and risk of bias not appraised.

Selected reported results and source limitations reviewed; not a complete risk-of-bias or experimental audit.

Sources checked

Citation

Patent / reported experimentsFull text available

Author unconfirmed. Cyclontane and sodium oxybate pharmaceutical composition for desynchronosis RU2674342C2; filed 28 November 2016; Russian Federation represented by Ministry of Defense

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards